These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 7533825

  • 1. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 2. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN, Chevallier B, Chevreau C, Krakowski I, Peny AM, Thyss A, Maugard-Louboutin C, Cupissol D, Fargeot P, Bonichon F.
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [Abstract] [Full Text] [Related]

  • 4. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 5. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
    Tjan-Heijnen VC, Biesma B, Festen J, Splinter TA, Cox A, Wagener DJ, Postmus PE.
    J Clin Oncol; 1998 Aug; 16(8):2708-14. PubMed ID: 9704721
    [Abstract] [Full Text] [Related]

  • 6. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ.
    J Clin Oncol; 2000 Jan; 18(2):395-404. PubMed ID: 10637255
    [Abstract] [Full Text] [Related]

  • 7. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J, George M.
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [Abstract] [Full Text] [Related]

  • 8. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
    Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG.
    J Clin Oncol; 1994 Jan; 12(1):77-82. PubMed ID: 7505809
    [Abstract] [Full Text] [Related]

  • 9. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
    de Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N.
    J Clin Oncol; 1995 Jul; 13(7):1623-31. PubMed ID: 7602351
    [Abstract] [Full Text] [Related]

  • 10. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE.
    Oncology; 1997 Jul; 54(5):363-70. PubMed ID: 9260596
    [Abstract] [Full Text] [Related]

  • 11. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.
    Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG.
    J Clin Oncol; 1995 Jan; 13(1):148-56. PubMed ID: 7528271
    [Abstract] [Full Text] [Related]

  • 12. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):533-41. PubMed ID: 18398095
    [Abstract] [Full Text] [Related]

  • 13. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B.
    Clin Oncol (R Coll Radiol); 1995 Apr 16; 7(5):293-9. PubMed ID: 8580054
    [Abstract] [Full Text] [Related]

  • 14. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun 16; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 15. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec 16; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N.
    J Natl Cancer Inst; 2005 May 04; 97(9):666-74. PubMed ID: 15870437
    [Abstract] [Full Text] [Related]

  • 17. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H, Naoki K, Narita Y, Hida N, Kunikane H, Watanabe K.
    Lung Cancer; 2006 Aug 04; 53(2):197-203. PubMed ID: 16781005
    [Abstract] [Full Text] [Related]

  • 18. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 04; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 19. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
    Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt PA, Stout R, Simms T, Davies R, Pettengell R.
    J Clin Oncol; 2001 Feb 01; 19(3):712-9. PubMed ID: 11157022
    [Abstract] [Full Text] [Related]

  • 20. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C, European Organization for Research and Treatment of Cancer-Lung Cancer Group.
    J Clin Oncol; 2002 Oct 01; 20(19):3947-55. PubMed ID: 12351591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.